Drug news

Napp Pharma to market Remsima in UK - Celltrion/Napp

Read time: 1 mins

Last updated:15th Aug 2014

Published:15th Aug 2014

Source: Pharmawand

Napp Pharmaceuticals has secured exclusive rights to distribute in the UK, Remsima (infliximab-biosimilar), from Celltrion being the biosimilar version of Johnson & Johnson and Merck & Co's anti-inflammatory Remicade (infliximab). Remsima, was recently filed with the FDA and is approved by the European Medicines Agency for all the indications of Remicade. The European patents on Remicade will expire in February 2015.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

Drug news

CHMP positive recommendation to change to marketing authorisation of Triumeq (abacavir sulfate / dolutegravir sodium / lamivudine) to treat HIV infections.-ViiV HealthCare

1 mins

Drug news

CHMP positive recommendation to change the marketing authorisation of Sirturo (bedaquiline) in patients with pulmonary tuberculosis.- Jansssen- Cilag (J&J)

On 25 April 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending a change to the terms of the marketing authorisation for the medicinal product Sirturo (bedaquiline). The marketing authorisation holder for this medicinal product is Janssen-Cilag International NV.

1 min

Drug news

CHMP positive recommendation to extend the marketing authorisation of Alecensa (alectinib hydrochloride).- Roche.

1 min

See all news